ADVI Health Accelerates Insights with Monthly Medicare Data

Market Access Strategic Analytics, Value and Economics

August 12, 2026

ADVI Health now has access to 100% of Medicare Parts A, B, and D research files with monthly availability – enabling faster, more responsive evidence generation and market insights.

What This Means for Our Clients and Partners
  • Timelier Insights: Near real-time visibility into utilization and outcomes.
  • Faster Evidence Generation: Accelerated health economics and outcomes research (HEOR), real-world evidence (RWE), and market access analytics aligned with evolving payer and policy needs.
  • Quicker Value Demonstration: Shorter data-driven evidence cycles.
  • Real-Time Market Awareness: Ongoing visibility into treatment patterns, competitive dynamics, and policy-driven shifts.

Why it Matters

In today’s evolving healthcare landscape, timing is everything. With monthly data access, ADVI enables faster, more responsive evidence generation, helping clients and partners stay ahead of change, demonstrate value sooner, and act with confidence.

Turning Data into Actionable Insights

ADVI combines timely Centers for Medicare and Medicaid Services (CMS) data with deep policy, HEOR, and market access expertise to uncover emerging trends and translate complex healthcare data into strategic insights.

ADVI Advantage

ADVI leverages high-frequency data and advanced analytics to deliver precise, timely, and actionable insights— strengthening our position as a leading partner for organizations seeking strategic, evidence-driven decision support in policy impacts, market access, and HEOR.


Medicare Drug Price Negotiation

Early Insights from Medicare Drug Price Negotiation

ADVI’s analysis of H1 2025 and H1 2026 data data reveals how the first year of Medicare drug price negotiation is affecting patient costs, prescription spending, and Part D plan design.

Patients Saw Minimal Decreases in Out-of-Pocket Expenses

Patient expenses decreased an average of only  $11.71 per prescription, which is a 9% decrease from 2025 to 2026 and aligns more with the average 2024 OOP.

Data based on 2025 and 2026 Q1 patient out-of-pocket costs across all IPAY drugs, weighted by claims volume

Out-of-Pocket Costs Increased for Some MFP Drugs

For some MFP drugs, out-of-pocket patient costs increased:

Data represents 2025 and 2026 Q1 and Q2 averages for non-low-income out-of-pocket patient costs by drug

Total Spending and Claim Volume Decreased Across MFP Drugs

Total spending and claim volume across all MFP drugs decreased from 2025 to 2026

Total prescription costs

Total claims

Data across all MFP drugs for January through June of 2024, 2025, and 2026   

Total spending and claim volume Increased Across All Part D Claims

Total spending and claim volume increased across all Part D claims from 2024 to 2026

Total prescription costs

Total claims

Data across all MFP drugs for January through June of 2024, 2025, and 2026   

$0 Deductible Part D Plan Enrollment Dropped Significantly

The proportion of enrollees in $0 deductible Part D plans dropped significantly from 2025 to 2026

Ready to Turn Data into Action?

Partner with ADVI Health to Turn Data into Impact—Faster


CEO insights

Real analysis from people who’ve been there

Health Policy & Access Strategy Inflation Reduction Act

Exclusive Webinar: Unpacking the Future of U.S. Drug Pricing Policy

Gain immediate access to actionable insights from CMS and ADVI Health policy leaders. From the Medicare Drug Price Negotiation Program …

October 2, 2026

Health Policy & Access Strategy Inflation Reduction Act

Analysis of 340B modifier usage in Medicare Part B claims

Analysis of Part B Claims from January 2025 through June 2026 Prepared By:Johanna Celli, Pete Kardel, Caitlin Sheetz, ADVI Health’s …

September 30, 2026

The Growing Relevance of HEOR: Turning Complex Healthcare Questions Into Actionable Evidence

For the first time, ISPOR added “Relevance of HEOR: Demonstrating the Field’s Vital Role in Health” to its Top 10 …

September 24, 2026

RAND/UCLA Modified Delphi Panels

ADVI Health partners with pharmaceutical and biotech organizations to advance their evidence generation and market access strategies. We support complex research questions through primary research (e.g., …

Caitlin Sheetz, MPH
June 23, 2026

Cell and Gene Precision Medicine State Policy

The 2026 Rare Disease Reality

Orphan drugs now represent approximately 20 percent of total prescription spend, and over 52 percent of the cell and gene …

Marc Samuels, JD, MPH
February 26, 2026

Health Policy & Access Strategy

How HEOR and Real-World Evidence Are Reshaping Decisions in 2026

By 2026, health economics and outcomes research (HEOR) and real-world evidence (RWE) will look less like a supporting function and …

February 10, 2026

Precision Medicine

FDA Proposes Down-Classification of Oncology Companion Diagnostics: A Q&A on Precision Medicine

The Food and Drug Administration (FDA) has announced a significant proposed change affecting oncology companion diagnostics (CDx) that could streamline …

December 16, 2025

Precision Medicine

2026 Life Sciences Forecast: AI, Next-Gen Cell & Gene Therapy, and Policy Disruption

In 2026, we expect the healthcare landscape to be defined by technology breakthroughs, market access disruption, and profound policy changes. …

Marc Samuels, JD, MPH
December 16, 2025

Reach out

Own your edge

We don’t just guide the market. We shape it. Map your market access moves with #ADVIIntelligence. Proven advantage. Unmatched partnership.